Yunus AKSÜT

Dr. Yunus AKSÜT

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Chemosphere
Verified
Journal Article
Closed access
ÖKÖnder Kılıç
Önder Kılıç
MBMurat Belivermiş
Murat Belivermiş
ESErcan Sıkdokur
Ercan Sıkdokur
NSNarin Sezer
Narin Sezer
Yunus AKSÜTYunus AKSÜT
Yunus AKSÜT
YGYusuf Can Gerçek
Yusuf Can Gerçek

3 August 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
OYOguz Yucel
Oguz Yucel
Yunus AKSÜTYunus AKSÜT
Yunus AKSÜT
Aslıhan ŞengelenAslıhan Şengelen
Aslıhan Şengelen
EYEren Yıldırım
Eren Yıldırım
SESerkan Emik
Serkan Emik
GGGulten Gurdag
Gulten Gurdag

25 March 2025 in Medical Oncology
Verified
Journal Article
Open access
PDF file
MPMurat Pekmez
Murat Pekmez
ŞMŞefika Beyza Mete
Şefika Beyza Mete
Yunus AKSÜTYunus AKSÜT
Yunus AKSÜT
IÖİrEm Öğütcü
İrEm Öğütcü
FBFATMA NUR BAŞTÜRK
FATMA NUR BAŞTÜRK
Aslıhan ŞengelenAslıhan Şengelen
Aslıhan Şengelen
Targeting cellular metabolism is becoming a critical approach for stopping cancer progression. Limited information is available regarding the effects of inhibiting the lipogenic enzyme fatty acid synthase (FASN) in glioblastoma (GB) cells (grade-IV-astrocytoma), which have high invasion and low response to standard treatments. Herein, we used cerulenin (CER) to inhibit FASN. CER treatments (3.6 μg/mL/48 h and 5.55 μg/mL/48 h indicate IC20 and IC50 values, respectively) led to a dose- and time-dependent decrease in the viability of the U-87MG human GB cells. A significant decrease was detected in the levels of fatty acids, including palmitic acid, determined by GS-MS analysis. FASN inhibition attenuated cell motility, 2D and 3D-clonogenic survival, and cell differentiation characteristics (related markers of epithelial-mesenchymal transition/EMT and stemness). Moreover, treatments caused mitochondrial membrane potential (MMP) collapse and increased intracellular reactive oxygen species (ROS) levels. Protein aggregates and ER stress in the cells also increased. Remarkably, despite increased Hsp70 and p-HSF1 levels against induced cellular stress, CER promoted markedly autophagy and apoptosis. The network pharmacology approach revealed that protein and lipid kinases are crucial targets in cell signaling, and PI3K, AKT, and NF-κB levels were confirmed by immunoblotting. The results demonstrated for the first time that inhibiting FA production and FASN function induces cell death through ROS generation and ER stress while simultaneously reducing the motility and aggressiveness of U-87MG human glioblastoma cells by attenuating EMT and stemness phenotypes. Therefore, blocking lipid metabolism using CER may be considered as a good candidate for GB therapeutic option.

2 January 2025 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
FBFerhat Bostancı
Ferhat Bostancı
Aslıhan ŞengelenAslıhan Şengelen
Aslıhan Şengelen
Yunus AKSÜTYunus AKSÜT
Yunus AKSÜT
EYEren Yıldırım
Eren Yıldırım
IÖİrEm Öğütcü
İrEm Öğütcü
MPMurat Pekmez
Murat Pekmez
Glioblastoma, with a low survival rate, is an aggressive and difficult-to-treat lethal type of brain cancer. Indomethacin (IND), a non-steroidal anti-inflammatory drug, has antitumoral activity in many cancers, including gliomas. However, its poor aqueous solubility is a critical issue. Nanomaterials are crucial tools for overcoming solubility problems and facilitating drug delivery. Herein, a polymeric nanoparticle system, poly(lactic-co-glycolic acid) (PLGA) was used to encapsulate IND. Although PLGA is an FDA-approved copolymer for drug delivery, no trials with IND-loaded PLGA-NPs have been conducted to treat brain tumors. Encapsulation success was revealed by DLS, zeta potential, TEM, and FTIR analysis; IND/PLGA-NPs had nanoscale particle size (160.6 nm), narrow size distribution (0.230, PDI), and good stability (-23.9 mV). Fluorescence imaging showed that PLGA-NPs can penetrate U-87MG cells. Short-term/one-hour treatment with bound-IND increased the free-IND effect in gliomas by similar to 10 times/48h and 12.39 times/72h. Even against long-term exposure to IND, IND/PLGA-NP treatment revealed a highly marked result; the IC50 value of bound-IND (treatment-time:1h, analysis at 48h) was similar to 200 mu M, IC50 value of free-IND (treatment-time:48h) was similar to 390 mu M. Furthermore, IND/PLGA-NPs' anticancer activity (100 mu M of IND/1h, analysis at 48h) was also supported by induced apoptosis and reduced migration/colony formation in glioma cells. All evidence suggests that IND/PLGA-NPs may be a potentially promising agent for treating gliomas.

19 May 2025 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
MYMerve Yılmazer
Merve Yılmazer
Aslıhan ŞengelenAslıhan Şengelen
Aslıhan Şengelen
Yunus AKSÜTYunus AKSÜT
Yunus AKSÜT
BPBEDIA PALABIYIK
BEDIA PALABIYIK
EUEvren Önay Uçar
Evren Önay Uçar
SUSemian Karaer Uzuner
Semian Karaer Uzuner

12 May 2021 in Archives of Medical Science
Verified
Journal Article
Closed access
Yunus AKSÜTYunus AKSÜT
Yunus AKSÜT
Introduction: Morus alba (white mulberry) pollen is an aero-allergen source that can trigger allergic diseases. Cobalamin-independent methionine synthase (MetE) in M. alba pollen has been proved to be one of the major allergens for some patients living in Istanbul (Turkey). The aim of the present study was the recombinant production and identification of MetE (Mor a 2), a novel allergen from M. alba pollen. The IgE binding reactivity of rMor a 2 produced for the first time was evaluated and some structural features were investigated by in silico methods to better understand its immunogenicity.Material and methods: The gene encoding Mor a 2 was cloned in fission yeast, Schizosaccharomyces pombe ura4-D18h- strain, using pSLF1073 vector. This is the first report of the production of recombinant pollen allergen in S. pombe. After the purification, immunoreactivity of rMor a 2 was confirmed by immunoblotting using sera of patient allergic to M. alba pollen. Besides, B-cell epitopes of rMor a 2 were predicted using various bioinformatic tools, namely Bioinformatics Predicted Antigenic Peptides, BepiPred 2.0 and Immune Epitope Database whereas T-cell epitopes were estimated using NetMHCIIpan-3.2 and NetMHCII 2.3 servers.Results: The immunoblotting analysis yielded 11 of 11 positive reactions to rMor a 2. In silico predictions exerted seven B-cell epitopes (22-33, 384-394, 407-423, 547-553, 571-577, 671-678, 736-741) and seven T-cell epitopes (54-62, 161-170, 197-205, 347-358, 622-630, 657-665, 756-764).Conclusions: These findings may help the use of rMor a 2 in the diagnosis and treatment of allergic diseases associated with M. alba and/or MetE.